uniQure's Huntington's disease BLA accepted for Priority Review by FDA

uniQure announced FDA acceptance of the ifezuntirgene inilparvovec Biologics License Application with a Priority Review designation and a PDUFA target date of May 1, 2027. The news marks a significant industry milestone as ifezuntirgene could become the first disease-modifying treatment for the disease.